If you were asked to name the symptoms of kidney cancer, you might guess blood in the urine, back pain, or a lump in the abdomen. You would be right - but here is the problem: by the time those classic symptoms appear together, the cancer is often at an advanced stage. In 2025, roughly 70% of kidney cancers are discovered entirely by accident on scans performed for unrelated reasons - a gallstone check-up, a routine annual health screen, or imaging after a minor injury. That is not bad news. It is, in fact, the best possible scenario.
An incidentally discovered kidney cancer is almost always at an early, curable stage. Understanding why kidney cancer hides so effectively, what warning signs occasionally appear, and who should be screened more actively can be genuinely life-saving - for you or someone in your family.
The "Incidentaloma" - Kidney Cancer Found by Chance
The term incidentaloma refers to a tumour found incidentally on imaging ordered for a completely different reason. For kidney cancer (renal cell carcinoma, or RCC), this is now the dominant pathway to diagnosis. A patient gets an ultrasound for abdominal discomfort and the radiologist reports "a 3 cm solid mass on the right kidney." Or a CT scan for a road traffic injury reveals a small tumour the patient had no idea existed.
The kidney is a retroperitoneal organ - tucked deep behind the abdominal cavity, cushioned by perirenal fat, behind the peritoneum. A tumour growing within the kidney has enormous room to expand before it causes pressure symptoms, invades surrounding tissue, or bleeds visibly. A 2 cm or even 4 cm tumour may cause absolutely no symptoms whatsoever. This anatomical reality is why kidney cancer earned its old reputation as "the internist's tumour" - a cancer that declared itself only when widespread.
The silver lining: as abdominal imaging has become more accessible across India - at annual health check-up packages, insurance medicals, and corporate screenings - more early-stage kidney cancers are being caught. At Apollo Hospital Gurugram, a significant proportion of the kidney cancers I operate on are Stage I or II, found at routine checks. That was not the case a decade ago.
The Classic Triad - and Why It Is Now a Late Warning
Medical textbooks describe the classic triad of kidney cancer: haematuria (blood in the urine), flank pain, and a palpable abdominal mass. Historically, this triad appeared in up to 15% of patients - and those patients nearly all had advanced disease. Today, with incidental detection so common, this triad occurs in fewer than 10% of newly diagnosed cases. When all three are present simultaneously, it should be treated as an oncological emergency requiring urgent CT imaging.
Each element deserves individual attention. Blood in the urine - even a single episode, even if it resolves completely - must be investigated with ultrasound and urine cytology. It is never safe to attribute haematuria to a urinary infection without ruling out cancer, particularly in anyone over 40. Flank pain from RCC is typically dull and persistent, unlike the sharp colic of a kidney stone. A palpable mass felt in the flank or upper abdomen may represent a very large tumour - these patients need imaging the same day.
Warning Signs of Kidney Cancer: What to Watch For
| Warning Sign | What It Means | Action Required |
|---|---|---|
| Blood in urine (haematuria) | Even a single episode is significant; often painless | Ultrasound + urine cytology immediately |
| Unexplained weight loss | Loss of >5% body weight without intentional dieting | Full blood count + abdominal imaging |
| Persistent flank or back pain | One-sided, dull, not related to posture or movement | Ultrasound abdomen; do not assume musculoskeletal |
| Unexplained fatigue & anaemia | Chronic anaemia without iron deficiency or obvious bleeding | Renal function tests + abdominal scan |
| Night sweats & low-grade fever | Paraneoplastic syndrome driven by tumour cytokines | Infection screen + renal imaging |
| New-onset hypertension | RCC can produce renin, elevating blood pressure | Renal ultrasound as part of hypertension workup |
| Palpable abdominal or flank mass | A firm, non-tender mass felt in the upper abdomen or flank | Urgent CT abdomen with contrast |
Who Is at Highest Risk of Kidney Cancer?
Kidney cancer does not strike randomly. The following groups have a materially higher lifetime risk and should consider annual abdominal ultrasound as part of routine health checks:
- Smokers and ex-smokers - tobacco is the single strongest modifiable risk factor, approximately doubling RCC risk. The elevated risk persists for years after quitting, though it does decline progressively.
- Obese individuals (BMI >30) - adipose tissue produces oestrogens and pro-inflammatory cytokines that drive renal carcinogenesis. A 10-unit increase in BMI raises RCC risk by approximately 25%.
- Patients with long-standing hypertension - both the condition itself and certain antihypertensive medications (particularly diuretics) are associated with increased risk.
- Patients on long-term dialysis - acquired cystic kidney disease in dialysis patients carries a 3–6 times higher risk of RCC. Annual surveillance ultrasound is recommended by international guidelines.
- Family history of kidney cancer - first-degree relatives of RCC patients have a 2–3 times higher lifetime risk. Hereditary syndromes (Von Hippel-Lindau disease, hereditary papillary RCC, Birt-Hogg-Dubé) account for 3–5% of all cases and often present at younger ages.
- Occupational exposures - trichloroethylene (used in metal degreasing industries), cadmium, and asbestos are recognised renal carcinogens with documented associations in occupational health studies.
How Kidney Cancer Is Diagnosed: The Investigation Pathway
The diagnostic pathway for a suspected renal mass follows a logical and well-validated sequence. An ultrasound abdomen is almost always the first test - widely available, radiation-free, and highly sensitive for identifying solid versus cystic masses. Any solid renal mass detected on ultrasound mandates further characterisation before any management decision is made.
A triphasic CT scan of the abdomen and pelvis with intravenous contrast is the gold standard. It determines the size, location, and internal architecture of the tumour; assesses the renal vein and inferior vena cava (IVC) for tumour thrombus - a critical finding that changes surgical planning; evaluates regional lymph nodes; and helps assess the contralateral kidney. Enhancement of the mass on contrast CT (the mass lights up after contrast injection) strongly suggests malignancy and mandates surgical referral.
A CT chest is performed to exclude pulmonary metastases - the lung is the most common site of RCC spread. If bone pain or elevated alkaline phosphatase is present, a bone scan is added to the workup. A renal biopsy is not routinely required before surgery - the CT appearance of a solid enhancing renal mass in an otherwise fit patient is sufficient indication for surgical intervention. Biopsy is reserved for patients where active surveillance or ablation is planned instead of surgery, requiring histological confirmation before committing to a non-operative approach.
Kidney Cancer Staging and 5-Year Survival Rates
| Stage | Description | 5-Year Survival |
|---|---|---|
| Stage I | Tumour ≤7 cm, entirely confined to kidney | 90–93% |
| Stage II | Tumour >7 cm, still confined to kidney | 74–79% |
| Stage III | Spread to renal vein, IVC, or local lymph nodes | 50–55% |
| Stage IV | Distant metastases (lung, bone, brain, liver) | 10–17% |
These figures make the case for early detection with mathematical clarity. Stage IV kidney cancer, while increasingly manageable with modern immunotherapy combinations (nivolumab + ipilimumab, pembrolizumab + axitinib), remains very difficult to cure. Stage I, caught incidentally on a routine ultrasound, is curable in over 9 out of 10 patients.
Watchful Waiting - Is Surgery Always Necessary?
Not every kidney tumour requires immediate surgery. For small renal masses (SRMs) under 4 cm - particularly in elderly patients with significant cardiac, pulmonary, or renal comorbidities where surgical risk is high - active surveillance is a recognised, evidence-based strategy. Multiple studies, including the DISSRM registry data, have shown that small renal masses grow slowly (average 0.3 cm per year), and progression to metastatic disease during surveillance is rare (fewer than 2% over 5 years).
Active surveillance involves 3-monthly imaging (ultrasound or CT alternately) in the first year, then 6-monthly if growth is reassuringly slow. The threshold to intervene with surgery or thermal ablation is typically growth exceeding 0.5 cm per year, or the mass approaching 4 cm in a fit patient. This approach preserves kidney function and avoids surgical risk in those who would benefit most from a conservative approach - it is not a "do nothing" strategy, but a carefully monitored one with clear decision points.
Robotic Partial vs Radical Nephrectomy - Choosing the Right Operation
When surgery is indicated, the choice between partial nephrectomy (removing only the tumour with a clear margin of normal kidney tissue) and radical nephrectomy (removing the entire kidney) depends on tumour size, anatomical position within the kidney, and the health of the contralateral kidney. International guidelines (EAU, AUA) recommend nephron-sparing surgery - partial nephrectomy - as the standard of care for all T1 tumours (under 7 cm) where technically feasible.
Robotic partial nephrectomy is the gold standard in experienced hands. The da Vinci robotic system provides 10x magnification, tremor filtration, and 7 degrees of instrument freedom - enabling precise tumour excision and multi-layer kidney reconstruction through 3 small port incisions (each less than 1 cm). The goal is to minimise warm ischaemia time (ideally under 20 minutes), ensure cancer-free surgical margins, and preserve maximum functioning kidney tissue. Patients typically spend 1–2 nights in hospital and return to normal activity within 3–4 weeks.
Radical nephrectomy - removing the entire kidney - is reserved for very large tumours, complex centrally-placed tumours where partial excision risks major vascular injury, or situations where the remaining kidney tissue after excision would be functionally insufficient. When radical nephrectomy is unavoidable, the robotic approach still offers the same advantages over open surgery: smaller incisions, less blood loss, faster return to activity, and equivalent oncological outcomes.
Learn more on our dedicated kidney cancer treatment and renal cell carcinoma pages, and read in detail about robotic partial nephrectomy and robotic urology surgery at Apollo Gurugram. If you have already received a diagnosis elsewhere, a specialist second opinion before committing to treatment is always worthwhile.
Video: Kidney Cancer - Detection & Surgical Treatment Explained
Found a kidney mass on your scan?
Dr. Nitin Shrivastava reviews all renal imaging and provides a clear, evidence-based treatment plan - at Apollo Hospital Gurugram or Six Sigma Clinics, Sector 50.
Book ConsultationFrequently Asked Questions
Back or flank pain can be a symptom of kidney cancer, but it is a late sign - occurring only when the tumour is large enough to stretch the kidney capsule or press on surrounding structures. Most early kidney cancers cause no pain at all. Persistent, dull, one-sided flank pain that does not improve with rest or physiotherapy warrants an ultrasound, but the majority of kidney cancers in 2025 are found incidentally on scans done for unrelated reasons - not because of pain.
Yes - Stage I kidney cancer (tumour confined to the kidney, under 7 cm) has a 5-year survival rate exceeding 90% with surgery. Stage II (larger but still confined) approaches 75–80%. The goal of robotic partial nephrectomy - removing only the tumour and sparing the rest of the kidney - is to achieve cure while preserving long-term kidney function. Early detection through routine health checks is therefore genuinely life-saving in kidney cancer.
Stage I renal cell carcinoma has a 5-year survival of approximately 90–93%. Stage II is around 74–79%. Stage III (spread to local lymph nodes or major veins) drops to 50–55%. Stage IV (distant metastasis) has a 5-year survival of 10–17%, though targeted therapies and immunotherapy have improved outcomes significantly in recent years. The key message is that survival is determined almost entirely by stage at diagnosis - which is why early detection matters enormously.
Kidney cysts are fluid-filled sacs - the vast majority are simple benign cysts (Bosniak I or II) that never require treatment. Kidney cancer is a solid mass of abnormal cells. On ultrasound, cysts appear as dark, well-defined, thin-walled structures; solid tumours appear as echogenic masses with internal structure. When a cyst has thick walls, internal septations, or solid components, a CT with contrast is performed to distinguish a complex cyst from cancer. The Bosniak classification system guides management.
Tumours over 4 cm are generally recommended for surgery (robotic partial or radical nephrectomy depending on position and complexity). Tumours between 2–4 cm in elderly patients or those with significant comorbidities may be managed with active surveillance or ablation. Tumours under 2 cm are often watched. However, size alone does not determine management - the Bosniak category, tumour location, patient age, kidney function, and overall fitness all factor into the decision. A specialist urologist should guide this choice individually.